Navigation Links
Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD
Date:10/30/2009

torical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company's products; the Company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company's products; the Company's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission.

SOURCE Shire plc


'/>"/>
SOURCE Shire plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Shire Continues to Deliver Excellent Growth From Core Products
2. Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30
3. Shire Presents Results of Five Lialda(R) (mesalamine) Analyses at ACG 2009 Annual Scientific Meeting
4. Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA
5. Shire and Sandoz Settle all Pending Litigation Concerning ADDERALL XR(R)
6. Veriscrip and DAMMAD Team Up to Combat Prescription Drug Abuse in New Hampshire
7. New Hampshire Rx Card Launching Statewide
8. Shire Announces FDA Approval of Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17
9. Shire Completes Submission of NDA for Velaglucerase Alfa for Type 1 Gaucher Disease and Reports Positive Results for Remaining Two Phase III Trials
10. Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... , July 1, 2015 ContraVir Pharmaceuticals, ... on the development and commercialization of targeted antiviral therapies, ... Fitzgerald Inaugural Healthcare Conference taking place in ... at Le Parker Meridien Hotel. ... overview of the Company,s business during his live presentation ...
(Date:7/1/2015)... Pa. , July 1, 2015 Precyse, ... and education, announced today that, as part of its ... an agreement to be acquired by investment firm Pamplona ... private equity investors, Altaris Capital Partners and NewSpring Capital, ... in 1999, has assisted nearly 5,000 healthcare facilities and ...
(Date:7/1/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/46q6x8/2015_strategies ... "2015 Strategies in the Home/Self Testing Market" ... 175-page report provides analysis of the major home/self ... pregnancy, ovulation, and occult blood. The report presents ... competitive profiles. The growing economic pressures ...
Breaking Medicine Technology:ContraVir to Present at Cantor Fitzgerald Inaugural Healthcare Conference 2Precyse Enters into Acquisition Agreement with Pamplona Capital Management 2Precyse Enters into Acquisition Agreement with Pamplona Capital Management 32015 Strategies in the Home/Self Testing Market 2
... - Phase II Data Indicate Overall and Disease-Free ... Results from an adjuvant trial in,high-risk melanoma patients ... (sargramostim) achieved disease-free and/or overall,survival. These findings, which ... at the 44th annual meeting of the American ...
... SUNNYVALE, Calif., June 5 Pharmacyclics, Inc.,(Nasdaq: ... from a Phase 1/2 study showing a,46 ... multiply recurrent,non-Hodgkin,s lymphoma (NHL) who were treated ... Yttrium-90 Ibritumomab Tiuxetan,(Zevalin(TM)), an approved antibody-targeted radiation ...
Cached Medicine Technology:Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients 2Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients 3Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients 4Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients 5Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkin's Lymphoma 2Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkin's Lymphoma 3Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkin's Lymphoma 4
(Date:7/2/2015)... ... 02, 2015 , ... Denver-based SlimGenics Weight Control Centers, the ... No. 14 on ColoradoBiz magazine’s Top 100 Woman-Owned Companies list. ColoradoBiz compiles the ... The award identifies outstanding woman-owned businesses that demonstrate excellence and success in the ...
(Date:7/1/2015)... Angeles, CA (PRWEB) , ... July 01, 2015 , ... ... the great outdoors. Yet, in many Middle-Eastern countries like Saudi Arabia and Dubai, the ... to relax in more temperate climates. Celebrity dentist Dr. Sam Saleh of ORA Dentistry ...
(Date:7/1/2015)... ... ... Sir Fazle Hasan Abed, BRAC’s founder and chairperson, was announced as the ... for his outstanding contribution to enhancing the world's production and distribution of food to ... Prize Foundation, announced this year’s winner at a ceremony at the State Department in ...
(Date:7/1/2015)... Seattle, WA (PRWEB) , ... July 01, 2015 ... ... culture war in this land of liberty. Americans have been arguing over laws ... was a particularly contentious period, as a forthcoming historical comparative biography by Cindy ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... today announced that its fifth annual Smile for a Lifetime Foundation (S4L) fundraising ... non-profit organization. In addition to supporting S4L in its mission to provide free ...
Breaking Medicine News(10 mins):Health News:ColoradoBiz Magazine Names SlimGenics #14 on Top 100 Woman-Owned Companies List 2Health News:ColoradoBiz Magazine Names SlimGenics #14 on Top 100 Woman-Owned Companies List 3Health News:Dr. Sam Saleh Invites Vacationing International Patients to Get a Same-Day Hollywood Smile During the July Travel Season 2Health News:Sir Fazle Hasan Abed Receives World Food Prize 2Health News:Sir Fazle Hasan Abed Receives World Food Prize 3Health News:Biography by Cindy Safronoff to be Released July 4 Explores an 1870s Marriage Debate Over Women’s Rights and the Implications of the American Revolution for Sexuality 2Health News:Biography by Cindy Safronoff to be Released July 4 Explores an 1870s Marriage Debate Over Women’s Rights and the Implications of the American Revolution for Sexuality 3Health News:Biography by Cindy Safronoff to be Released July 4 Explores an 1870s Marriage Debate Over Women’s Rights and the Implications of the American Revolution for Sexuality 4Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 2Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 3
... ... every 6 men in the United States (1 in 3 in the African American community), ... by registering for Little Red Door,s Unite 2 Fight Race Against Prostate Cancer. , ... Indianapolis, IN (PRWEB) April 13, 2010 ...
... ... Multiple Sclerosis through Community , ... (PRWEB) April 13, 2010 -- Motivational Speaker/MS Advocate and Author Erin Morrow ... with Multiple Sclerosis. , , ,Published by iUniverse with a forward by Harold ...
... social fear and appear open, friendly to all, researchers ... Children with a rare condition called Williams syndrome appear ... a new study shows. , The finding suggests that ... stereotyping. , French and German researchers examined the behaviors ...
... Alzheimer,s patients with dignity and respect, researchers say ... memory loss can still "remember" feelings associated with happy ... University of Iowa researchers showed clips of happy and ... patients couldn,t remember what they had watched, but they ...
... Americans (96 percent of Republicans, 10 percent of Democrats ... care reform legislation that was signed into law by ... national survey conducted April 6 - 10 by researchers ... Research (CHPPR). Americans 18 to 34 years ...
... TCT 2010 (Transcatheter Cardiovascular Therapeutics) will provide ... in interventional cardiology that will directly affect patient ... interventional cardiology has figured prominently in recent current ... received a heart stent in February at New ...
Cached Medicine News:Health News:Registration Now Open for Little Red Door's Unite 2 Fight Race Against Prostate Cancer Saturday, July 10, 2010 2Health News:Author Erin Morrow Still Releases "Fighting MS: Strength in Numbers" 2Health News:Author Erin Morrow Still Releases "Fighting MS: Strength in Numbers" 3Health News:Kids With Rare Condition Lack Racial Prejudice 2Health News:Even As Memory Fades, Emotions Linger 2Health News:Health care reform 'important' even to those who want new law repealed 2Health News:TCT 2010 to have significant impact on interventional cardiology practices and patient care 2
Provides outstanding patient warming and safety throughout the hospital and is nearly half the size and one-third the weight of earlier units....
The SnuggleWarm Convective Warming provides the technology and the tools to effectively enhance the quality of patient care....
The product, which is comprised of a non-intrusive panty-liner, offers a simple to use classification tool that uses color identification for interpretation of the results....
The Affirm™ VPIII tests RNA probe technology offers a dependable, rapid means toward early identification and treatment of patients suffering from these pathogens....
Medicine Products: